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Renal denervation (RDN) is one of the most frequently used invasive methods for the treatment of 
arterial hypertension. However, recent randomized sham-controlled studies raised concern about 
the efficacy and predictability of response. We retrospectively analyzed outcomes of patients, who 
underwent RDN in our hypertension center between November 2010 and April 2014 and report here 
outcomes twelve months after procedure based on 24-hours ambulatory blood pressure monitoring. 
We defined ten-mm Hg decrease in office systolic blood pressure (SBP) as a cut-off for response and 
looked for possible predictors of this response using binary multiple regression analysis. 42 patients were 
included. Their mean age was 59.6 ± 9.2 years and 24% were female. Baseline office SBP and diastolic 
blood pressure (DBP) were 164.1 ± 20.3 and 91.8 ± 12.4 mm Hg respectively. Mean 24 h-SBP significantly 
decreased from 149.8 ± 13.3 mm Hg to 141.2 ± 14.6 mm Hg. Mean 24 h-DBP significantly decreased from 
83.3 ± 11.7 mm Hg to 78.8 ± 11.2 mm Hg. A higher level of mean 24 h-DBP and office DBP was shown to 
be predictive for response in office BP and a higher level of mean 24 h-DBP for response in 24 h-SBP and 
24 h-DBP. Further properly designed randomized trials are warranted to confirm this finding as well as 
further investigate the role of diabetes mellitus and arterial stiffness in RDN.
Arterial hypertension has a major disease burden. Percutaneous renal denervation (RDN) has been shown to 
effectively reduce blood pressure (BP) in different previous trials1–3. However, reported responses vary from large 
falls in BP to unchanged or small increase in BP even within a given study population4. This suggests, that spe-
cific patient characteristics may predict the response to RDN. Establishing such predictors is very important for 
clinicians since significant fall in BP after RDN could cause more morbidity due to hypotension, whereas poor 
response would not be expected to reduce cardiovascular events, which is the primary purpose of BP reduction. 
The randomized and sham-controlled SIMPLICITY-HTN 3 trial could not show any benefit of RDN compared 
to sham-group with optimal medical treatment5 and raised doubt about the effectiveness of RDN, though reliable 
data support the “proof of concept” of RDN6,7. Recently published sham-controlled Spyral HTN ON-MED and 
OFF-MED studies demonstrated clinically relevant fall in 24-hours ambulatory systolic BP (SBP) with 7.4 mm 
Hg after six months in the ON-MED trial and 5.5 mm Hg after three months in the OFF-MED trial8,9. In the 
sham-controlled, prospective, double-blind Radiance-HTN solo trial, where an intravascular applied ultrasound 
was used for renal artery nerve ablation, 24-h-SBP reduction of 5 mm Hg was observed10. Both studies showed a 
clear tendency for the effectiveness of the RDN procedure. However, the magnitude of response was unpredicta-
ble with some over-responder and only about 70–80% presenting with any BP reduction after RDN.
In the light of current data, identification of the predictors for response to RDN seems to be crucial in order 
to select the patients appropriately. The response should be evaluated according to change in mean 24 h-SBP and 
diastolic BP (DBP) obtained with ambulatory blood pressure monitoring (ABPM), due to known shortcomings 
of office BP11. Based on ABPM readings, more data are needed from a “real-world setting” dealing with reliable 
predictors of the response to RDN. In this retrospective analysis, we sought to identify such baseline parameters 
in a cohort of patients with refractory hypertension, who underwent RDN in our centre. We considered changes 
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in 24 h-BP measured with ABPM in order to avoid shortcomings related to office BP-based assessment of treat-
ment effect.
Results
In total, 81 patients underwent RDN in our nephrology and hypertensiology department at Charité University 
Berlin, Campus Benjamin Franklin between November 2010 and April 2014. Complete demographic, clinical 
and procedure-related data and follow-up data including the course of BP values assessed with ambulatory blood 
pressure monitoring over 24 hours (24 h-ABPM) was available for 42 subjects, who were included in our retro-
spective analysis. According to the chosen response definition, twenty-one patients showed BP-response after 
RDN. Mean patient age, BMI, kidney function, amount of albuminuria, office SBP and DBP, heart rate and the 
number of antihypertensive medications at baseline and after twelve months did not differ significantly in both 
groups. In the responder group, the mean 24 h-SBP and -DBP at baseline were significantly higher compared to 
the non-responder group. In the non-responder group the number of patients with diabetes was significantly 
higher than in the responder group. Details of demographics and clinical data of the whole collective, responder 
and non-responder group are presented in Table 1.
During RDN 9.9 ± 3.6 ablations were performed. As shown in Table 2 there was no statistically significant 
difference in procedure-related parameters such as the diameter of renal arteries, the distance between the origin 
of the renal artery and the last ablation point, the number of ablation points, or the anatomy of renal arteries.
We observed a significant decline in mean 24 h-SBP and 24 h-DBP in the whole group and the responder 
group twelve months after RDN. Non-responder did not show any significant change in 24 h-SBP and 24 h-DBP. 
Details for whole group, responder and non-responder are shown in Table 3. Individual changes in 24-h mean 
SBP and DBP from baseline to twelve months are presented in Fig. 1. 24 h-SBP and -DBP mean changes at two 
days, one month, three months, six months, nine months and twelve months after RDN are shown in Fig. 2.
In the univariate analysis significantly different parameters between responder and non-responder group (see 
Table 1) and age, sex, BMI, baseline office SBP and DBP, eGFR, heart rate, and ISH were inputted in a binary 
logistic regression. For prediction of response to RDN the odds ratio of baseline office DBP and 24 h-ABPM DBP 
was 1.2 [95% CI 1.0 to 1.5; p = 0.045] and 1.5 [95% CI 1.1 to 1.9; p = 0.007] respectively; the odds ratio of baseline 
24 h-ABPM SBP and diabetes mellitus were 1.01 [95% CI 0.9 to 1.1, non-significant] and 2.9 [95% CI 0.3 to 26.2, 
non-significant] (Fig. 3). We also performed multiple linear regression analysis for change in mean 24 h-SBP 
and 24 h-DBP including the same independent variables as in the analysis of predictive effect based on defined 
response cut-off (>10 mm Hg change in office SBP). In this analysis, baseline mean 24 h-DBP predicted signifi-
cantly decrease in mean 24 h-SBP (p = 0.003) and mean 24 h-DBP (p = 0.001) after RDN.
The particular analysis of diabetic patients showed significantly higher baseline mean 24 h-SBP (154.3 ± 13.7 
vs. 145 ± 11.5 mm Hg, p = 0.001) and mean 24 h-DBP (88.9 ± 10.0 vs. 77.6 ± 10.6 mm Hg, p = 00.1) compared to 
non-diabetics. Both mean 24 h-SBP and 24 h-DBP did not change significantly twelve months after RDN in dia-
betic patients (Fig. 4). Prevalence of isolated systolic hypertension was 33% in non-diabetics and 67% in diabetic 
patients (p = 0.06).
Discussion
In this study, we performed a retrospective analysis regarding the BP-lowering effect of RDN-procedure in 
our center. We saw a clinically relevant reduction in 24 h mean SBP (8.6 mm Hg) and mean DBP (4.5 mm Hg). 
Observed amount of BP-reduction is comparable with the findings of recent randomized sham-controlled trials, 
which were explicitly designed to eradicate known limitations of RDN trials8–10. In addition to the inclusion of 
the sham procedure and assessment of BP-lowering effect based on results of ABPM, investigators also performed 
RDN in subjects without any antihypertensive medication (OFF MED approach) to assess the real effect of RDN 
on BP. Furthermore, in the case of electrical RDN, the ablation procedure was performed with the latest gener-
ation multielectrode catheter and generator8,9. Acknowledging the sophisticated trial design and improvements 
in ablation techniques, our patients had similar BP response after RDN compared to patients from above men-
tioned modern RDN-trials. This circumstance underlines the reliability of our data. Worth mentioning, baseline 
24 h-DBP in SPYRAL HTN-ON and -OFF MED trials was substantially higher than in our analysis.
We choose to dichotomize the BP-response after RDN and set the cut-off by ≥10 mm Hg fall in office SBP as 
already done in previous studies12,13. We observed a statistically significant independent impact of baseline office 
DBP and mean 24 h-DBP on response to RDN using multiple binary regression analysis. Significant predictive 
effect of mean baseline 24-h DBP also remained, when the BP-lowering effect was assessed as a continuous vari-
able using multiple linear regression analysis.
Virtually all previously published RDN studies identified baseline BP as the major primary determinant of 
BP response after RDN: Symplicity HTN-1 Investigators reported the issue for office BP response already in the 
initially published results14. Randomized sham-controlled SIMPLICITY HTN 3 trial confirmed these findings. 
Various registry analyses including experiences from different countries also found baseline BP as a major predic-
tor of BP-lowering effect after RDN and confirmed data coming from proof-of-concept studies and randomized 
trials by the evidence from real-life setting15–21. Noteworthy, baseline SBP predicted lowering effect in SBP and 
baseline DBP predicted lowering effect in DBP in all previously mentioned studies. In contrast, we observed base-
line office DBP and 24 h-DBP being predictors for the fall in SBP (office and 24 h-ABPM). To our knowledge, this 
finding has not been reported yet and thus extends available evidence. A possible biological explanation could be 
that higher DBP might reflect arterial vessels without severe and irreversible wall damage. Profound arterioscle-
rosis leads to increased arterial stiffness, higher pulse wave velocity (PWV), lower DBP and increased prevalence 
of isolated systolic hypertension (ISH)22. In this case, sympathetic overdrive is probably not a dominant driving 
mechanism of refractory arterial hypertension and thus associated with impaired response to RDN. Growing 
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evidence supports this hypothesis that patients with advanced arterial stiffness and thus severe arterial wall dam-
age as indicated by increased PWV23, aortic calcifications24 or ISH16,25 showed attenuated BP response after RDN.
One of the major causes of arteriosclerosis is diabetes mellitus. However, the impact of diabetes mellitus on 
BP response failed the statistical significance in multiple regression analysis, though it has shown a statistically 
significant negative impact on the BP response after RDN in univariate analysis among our patients. Further anal-
ysis of the subgroups with and without diabetes mellitus revealed that the former had significantly higher mean 
baseline SBP and DBP in ABPM, which could attenuate the effect of diabetes mellitus in the statistical analysis. 
Furthermore, patients with diabetes had also numerically more ISH compared to the group without diabetes. 
Lower baseline DBP and higher prevalence of ISH in non-responders and diabetic patients could be an expression 
of increased arterial stiffness and thus poorer response to RDN in our collective.
One of the strengths of our analysis is that the response to RDN was assessed with office BP measurements 
and ABPM, though patients were classified as responder or non-responder according to the amount of office SBP 
change. However, grouping in responder and non-responder according to office BP response reflected the response 
of 24-h ambulatory SBP and DBP in our analysis very well. As already shown, office BP might have some potential 
confounding characteristics such as “regression to the mean” phenomenon and white coat hypertension, which sig-
nificantly influence the amount of BP change over time8. These phenomena could be in part eliminated by ABPM11.
We acknowledge several limitations of our analysis. Our findings were obtained from a single centre and 
analysed in a retrospective fashion. Thus, looking for potential predictors of response to RDN our findings reflect 
associations and can only generate a possible hypothesis, which should then be tested in appropriately designed 
prospective studies. Relatively small number of the included patients and open non-blinded design of the anal-







Age, years 59.6 ± 9.2 61.4 ± 8.3 57.7 ± 9.8
Female sex, n (%) 10 (24) 5(24) 5 (24)
BMI, kg/m2 30.1 ± 4.6 30.4 ± 4.1 29.8 ± 5.11
Diabetes, n (%) 21 (50) 15 (71.4) 6 (28.6)*
    HbA1C, % 6.3 ± 1.0 6.0 ± 0.84 6.5 ± 1.0
eGFR, ml/min/1,73 m2 81.3 ± 16.0 78.6 ± 18.1 84.1 ± 13.2
    albuminuria, mg/g creatinine 73 ± 338 162 ± 535 14 ± 18
Isolated systolic hypertension, n(%) 12 (57.1) 6 (28.6)
coronary artery disease 6 (29) 6 (29)
Office SBP at baseline (mm Hg) 164.1 ± 20.3 163 ± 22.7 165.2 ± 18.0
Office DBP at baseline (mm Hg) 91.8 ± 12.4 89.2 ± 13.9 97.0 ± 16.1
24-h mean SBP (mm Hg) 149.8 ± 13.3 144.5 ± 13.1 155.1 ± 11.4*
24-h mean DBP (mm Hg) 83.3 ± 11.7 77.0 ± 10.8 89.4 ± 9.1#
Heart rate at baseline (bpm) 65.5 ± 10.0 64.8 ± 11.8 66.1 ± 8.1
Antihypertensives at baseline 5.5 ± 1.4 5.9 ± 1.1 5.2 ± 1.7
    ACEI/ARB, n(%) 39 (92.9) 20 (95.2) 19 (90.5)
    Calcium channel blocker, n(%) 35 (83.3) 19 (90.5) 16 (76.2)
    Betablocker, n(%) 34 (81.0) 17 (81.0) 17 (81.0)
    Aldosterone antagonist, n(%) 5 (11.9) 4 (19.0) 1 (4.8)
    Thiazide, n(%) 39 (92.9) 20 (95.2) 19 (90.5)
    Nitrates, n(%) 9 (21.4) 4 (19) 5 (23.8)
    Central alpha2-agonists, n(%) 22 (52.4) 13 (61.9) 9 (42.9)
    Direct vasodilators, n(%) 7 (9.5) 5 (23.8) 2 (9.5)
Antihypertensives at 12 months 5.1 ± 1.2§ 5.2 ± 1.0 4.9 ± 1.4
    ACEI/ARB, n(%) 38 (90.5) 20 (95.2) 18 (85.7)
    Calcium channel blocker, n(%) 29 (69.0) 15 (71.4) 14 (66.7)
    Betablocker, n(%) 36 (85.7) 17 (81) 19 (90.5)
    Aldosterone antagonist, n(%) 5 (11.9) 3 (14.3) 2 (9.5)
    Thiazide, n(%) 41 (97.6) 21 (100.0) 20 (95.2)
    Nitrates, n(%) 5 (11.9) 4 (19) 1 (4.8)
    Central alpha2-agonists, n(%) 18 (42.9) 9 (42.9) 9 (42.9)
    Direct vasodilators, n(%) 11 (26.2) 5 (23.8) 6 (28.6)
Table 1. Demographic and clinical characteristics of the study collective (n = 42). ACEI- angiotensin 
converting enzyme inhibitor; ARB- angiotensin receptor blocker; BMI- body mass index; DBP- diastolic 
blood pressure; SBP- systolic blood pressure; *statistically significant difference compared to non-responder 
(p < 0.01); #statistically significant difference compared to non-responder (p < 0.001); §statistically significant 
difference compared to the number of antihypertensives at baseline (p < 0.01).
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studies. Keeping the potentially higher risk of confounding in mind, our results show a similar response to RDN 
compared to recent second-generation sham-controlled randomized studies8–10.
Testing patient compliance was not a part of clinical routine during the follow up after the RDN in our collec-
tive. Thus, confounding of the BP-lowering effect of RDN by varying medication intake cannot be ruled out. It 
is a common problem of all RDN studies or analyses, which included patients on antihypertensive medications 
without compliance testing as an inclusion criterion or as a part of follow up. We cannot distinguish the true 
resistant hypertensive patients from the patients who are incompliant to their antihypertensive drugs. Among the 
non-responders in our study collective, the BP increased over time. A possible explanation of this finding could 
be the higher amount of incompliant patients, who took their medication in preparation to RDN and shortly after 
and then reduced or stopped it.
The cut-off margin for responder was defined for office BP based on previous studies18. Study findings 
could thus not be generally translated to response in ABPM and other cut-offs for a definition of responder vs. 
non-responder to RDN. Hence, we additionally looked for response predictors for change in mean 24 h-SBP 
and mean 24 h-DBP in ABPM and could demonstrate that higher baseline 24-DBP, but not baseline office DBP, 
significantly predicted a higher decrease of mean 24 h-SBP and 24 h-DBP 12 months after RDN. In our analysis, 
we showed the trend for diabetes mellitus to be a predictor for negative RDN response, which failed to remain 
statistically significant in the multiple logistic regression. This could be due to a relatively small study collective 
and further prospective studies directly approaching this issue with more patients are needed.
Recently released new guidelines on the management of hypertension by European Society of Hypertension 
and European Society of Cardiology do not recommend to use RDN in the clinical routine as hypertension 
treatment method anymore. One of the concerns leading to this recommendation was insufficient data about the 
suitable subpopulation of hypertensive patients and lack of predictors for RDN response26.
The primary conclusion and clinical implication from our study are that DBP, measured in office and with 
ABPM, seems to be a predictor of response to RDN. Given that lower DBP could be a reflection of increased arte-
rial stiffness and more advanced arterial wall damage, our data add to the available evidence pointing to impaired 
response to RDN in patients with increased arterial stiffness. Further properly designed randomized trials are war-
ranted to confirm this finding as well as further investigate the role of diabetes mellitus and arterial stiffness in RDN.
Methods
This retrospective analysis was performed according to the Declaration of Helsinki and written informed con-
sent was obtained from all patients included. The local ethics committee (ethics committee of Charité Medical 
University Berlin, Germany) approved the study. There is no restriction on the availability of additional materials 
or information, which can be any time obtained by sending a query to the corresponding author via email.
Patients were considered to have resistant hypertension, when the mean of three measurements of office sys-
tolic blood pressure was >140 mm Hg and/or of office DBP >90 mm Hg respectively and the mean SBP >130 mm 
Hg and mean DBP >80 mm Hg with 24 hours ambulatory blood pressure monitoring. 81 patients with resistant 
hypertension underwent RDN between November 2010 and April 2014. All of them were treated with at least 




n = 21 p-value
Standard anatomy of renal arteries, n(%)* 11(52.4) 15(71.4) ns
Sum of the ablation points 10.4 ± 4.2 9.3 ± 2.7 ns
Diameter of the right renal artery, mm 7.0 ± 1.5 7.1 ± 1.1 ns
Diameter of the left renal artery, mm 7.1 ± 1.4 7.3 ± 1.1 ns
Distance ostium RRA-last ablation point, mm 39.5 ± 14.5 39.7 ± 13.0 ns
Distance ostium LRA-last ablation point, mm 37.6 ± 9.1 40.3 ± 12.4 ns
Table 2. Renal denervation procedure characteristics. *Standard anatomy, considered when single renal artery 




24-hours SBP (mm Hg)
   Whole collective 149.8 ± 13.3 141.2 ± 14.6 0.001
   Responder 155.1 ± 11.4 135.0 ± 14.6 <0.001
   Non-responder 144.5 ± 13.1 147.4 ± 11.8 0.26
24-hours DBP (mm Hg)
   Whole collective 83.3 ± 11.7 78.8 ± 11.2 0.007
   Responder 89.5 ± 9.1 78.1 ± 9.1 <0.001
   Non-responder 77.0 ± 10.8 79.5 ± 13.1 0.052
Table 3. 24-hours systolic (SBP) and diastolic (SBP) blood pressure at baseline and twelve months after renal 
denervation.
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Common secondary causes of hypertension such as sleep apnea syndrome, hemodynamic significant renal artery 
stenosis, hyperaldosteronism, hypercortisolism, abnormality of thyroid function and pheochromocytoma were 
excluded prior to RDN.
Further exclusion criteria were pregnancy, age below 18 years, implanted peacemaker or intracardiac defibril-
lators, severe cardiac valve abnormalities and renal artery diameter <4 mm or length of renal artery <20 mm. 
Renal artery anatomy was checked before intervention by either CT-angiography or MR-angiography.
For RDN, the Symplicity RDN Catheter System (Medtronic Inc., Minneapolis, Minnesota, USA) was used via 
the right femoral approach. RDN procedure was performed in both renal arteries during the same session with 
a minimum of five ablation points in each renal artery. The RDN procedure was performed under general anes-
thesia. We defined the bilateral presence of single renal artery without any anatomical abnormalities as “standard 
anatomy”; any other case was defined as “non-standard” anatomy.
Figure 1. Individual changes in 24 h systolic and diastolic blood pressure from baseline to 12 months after renal 
denervation; grey bars represent responder and black bars represent non-responder.
Figure 2. Mean changes in 24 h ambulatory systolic and diastolic blood pressure at 2 days, 1, 3, 6, 9 and 12 
months after RDN (pp- post procedure); whiskers represent standard deviation.
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Routine clinical follow-up visits were performed after two days, one month, three months, six months, nine 
months, and twelve months. During each visit routine blood tests including assessment of kidney function and 
albuminuria were taken, information about current medication was collected and office blood pressure meas-
urement, as well as ABPM were performed. ABPM was performed using Spacelabs 90207-2 device (Spacelab 
Healthcare, Snoqualmie, WA 98065 US). The interval between 0600 to 2200 was defined as daytime (readings 
every 20 minutes) and the interval between 2200 and 0600 was defined as night-time (readings every 30 minutes). 
The cuff was placed on the non-dominant upper arm and patients were instructed to keep their arm calm dur-
ing the measurement. 42 patients with complete data for ABPM readings at baseline and after 12 months were 
included in this retrospective analysis.
Whenever a reduction in office SBP achieved ≥10 mm Hg after twelve months compared to baseline, the 
patient was considered to be a responder to RDN.
Isolated systolic hypertension was defined as the presence of SBP >140 mm Hg with simultaneously DBP 
≤90 mm Hg detected with office measurements or with ABPM.
Statistical Analysis. Continuous variables are expressed as mean with standard deviation. Presence of nor-
mal distribution was assessed with the Kolmogorov Smirnov test. In case of normal distribution, we used the 
t-test for comparison. In case of non-normal distribution, we used the Mann-Whitney-U test for comparison.
Discrete parameters are expressed as the number of patients and percentages. The differences were compared 
using χ2-test.
A multiple binary logistic regression analysis with stepwise forward inclusion model was applied to determine 
the predictors of RDN response after twelve months.
The level of significance used for all tests was a two-sided p-value of 0.05.
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